6.
Martin-Trejo J, Nunez-Enriquez J, Fajardo-Gutierrez A, Medina-Sanson A, Flores-Lujano J, Jimenez-Hernandez E
. Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study. Leuk Lymphoma. 2016; 58(4):898-908.
DOI: 10.1080/10428194.2016.1219904.
View
7.
Aristizabal P, Rivera-Gomez R, Chang A, Ornelas M, Ramirez M, Tamayo G
. Childhood Leukemia Survival in the US-Mexico Border: Building Sustainable Leukemia Care Using Health Systems Strengthening Models. JCO Glob Oncol. 2023; 9:e2300123.
PMC: 10497272.
DOI: 10.1200/GO.23.00123.
View
8.
Curado M, Pontes T, Guerra-Yi M, de Camargo Cancela M
. Leukemia mortality trends among children, adolescents, and young adults in Latin America. Rev Panam Salud Publica. 2011; 29(2):96-102.
DOI: 10.1590/s1020-49892011000200004.
View
9.
Abou Dalle I, Jabbour E, Short N
. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020; 11:2040620720910023.
PMC: 7065280.
DOI: 10.1177/2040620720910023.
View
10.
Othus M, Wood B, Stirewalt D, Estey E, Petersdorf S, Appelbaum F
. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016; 30(10):2080-2083.
PMC: 5053842.
DOI: 10.1038/leu.2016.120.
View
11.
Dai Q, Liu R, Wang Y, Ye L, Peng L, Shi R
. Longer Time Intervals From Symptom Onset to Diagnosis Affect the Overall Survival in Children With Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2021; 44(6):285-292.
DOI: 10.1097/MPH.0000000000002344.
View
12.
Aguirre-Guillen W, Angeles-Floriano T, Lopez-Martinez B, Reyes-Morales H, Zlotnik A, Valle-Rios R
. Omics techniques and biobanks to find new biomarkers for the early detection of acute lymphoblastic leukemia in middle-income countries: a perspective from Mexico. Bol Med Hosp Infant Mex. 2018; 74(3):227-232.
DOI: 10.1016/j.bmhimx.2017.03.007.
View
13.
Kinkorova J
. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2016; 7:4.
PMC: 4762166.
DOI: 10.1186/s13167-016-0053-7.
View
14.
de Rooij J, Zwaan C, Heuvel-Eibrink M
. Pediatric AML: From Biology to Clinical Management. J Clin Med. 2015; 4(1):127-49.
PMC: 4470244.
DOI: 10.3390/jcm4010127.
View
15.
Panuciak K, Nowicka E, Mastalerczyk A, Zawitkowska J, Niedzwiecki M, Lejman M
. Overview on Aneuploidy in Childhood B-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2023; 24(10).
PMC: 10218510.
DOI: 10.3390/ijms24108764.
View
16.
Zapata-Tarres M, Balandran J, Rivera-Luna R, Pelayo R
. Childhood Acute Leukemias in Developing Nations: Successes and Challenges. Curr Oncol Rep. 2021; 23(5):56.
DOI: 10.1007/s11912-021-01043-9.
View
17.
Juarez-Avendano G, Luna-Silva N, Chargoy-Vivaldo E, Juarez-Martinez L, Martinez-Rangel M, Zarate-Ortiz N
. Poor Prognosis Biomolecular Factors Are Highly Frequent in Childhood Acute Leukemias From Oaxaca, Mexico. Technol Cancer Res Treat. 2020; 19:1533033820928436.
PMC: 7340349.
DOI: 10.1177/1533033820928436.
View
18.
Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling A, Gaipa G, Bartels M
. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2016; 129(3):347-357.
PMC: 5291958.
DOI: 10.1182/blood-2016-07-726307.
View
19.
Kim I
. Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation. Blood Res. 2020; 55(S1):S19-S26.
PMC: 7386891.
DOI: 10.5045/br.2020.S004.
View
20.
van Dongen J, Lhermitte L, Bottcher S, Almeida J, van der Velden V, Flores-Montero J
. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-75.
PMC: 3437410.
DOI: 10.1038/leu.2012.120.
View